ATE213411T1 - Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen - Google Patents
Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungenInfo
- Publication number
- ATE213411T1 ATE213411T1 AT94903295T AT94903295T ATE213411T1 AT E213411 T1 ATE213411 T1 AT E213411T1 AT 94903295 T AT94903295 T AT 94903295T AT 94903295 T AT94903295 T AT 94903295T AT E213411 T1 ATE213411 T1 AT E213411T1
- Authority
- AT
- Austria
- Prior art keywords
- phenserine
- medications
- treatment
- production
- cognitive disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/980,399 US5409948A (en) | 1992-11-23 | 1992-11-23 | Method for treating cognitive disorders with phenserine |
PCT/US1993/011423 WO1994012176A1 (en) | 1992-11-23 | 1993-11-23 | Use of phenserine to treat cognitive disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE213411T1 true ATE213411T1 (de) | 2002-03-15 |
Family
ID=25527533
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT94903295T ATE213411T1 (de) | 1992-11-23 | 1993-11-23 | Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen |
Country Status (11)
Country | Link |
---|---|
US (1) | US5409948A (de) |
EP (1) | EP0668763B1 (de) |
JP (1) | JP3778363B2 (de) |
AT (1) | ATE213411T1 (de) |
AU (1) | AU693428B2 (de) |
CA (1) | CA2149924C (de) |
DE (1) | DE69331605T2 (de) |
DK (1) | DK0668763T3 (de) |
ES (1) | ES2173111T3 (de) |
PT (1) | PT668763E (de) |
WO (1) | WO1994012176A1 (de) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9806184A (pt) * | 1997-07-09 | 2001-06-19 | Axonyx | Inibidores de butirilcolinesterase altamente seletivos para o tratamento e o diagnóstico da doença de alzheimer e demências |
US20030125609A1 (en) * | 2001-08-03 | 2003-07-03 | Robert Becker | Method for reliable measurement in medical care and patient self monitoring |
US6495700B1 (en) | 2002-01-09 | 2002-12-17 | Axonyx, Inc. | Process for producing phenserine and its analog |
US7612078B2 (en) | 2003-03-31 | 2009-11-03 | Epix Delaware, Inc. | Piperidinylamino-thieno[2,3-D] pyrimidine compounds |
US7897639B2 (en) * | 2003-10-21 | 2011-03-01 | Colucid Pharmaceuticals, Inc. | Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents |
US20050182044A1 (en) * | 2004-02-17 | 2005-08-18 | Bruinsma Gosse B. | Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate |
EP1740172A4 (de) * | 2004-03-19 | 2007-10-10 | Axonyx Inc | Acetylcholinesterase-hemmer und n-methyl-d-aspartat-antagonisten zur behandlung von kognitiven störungen |
WO2005089746A1 (en) * | 2004-03-19 | 2005-09-29 | Axonyx, Inc. | Dosage titration for treatment of cognitive disorders |
US7488736B2 (en) | 2004-05-17 | 2009-02-10 | Epix Delaware, Inc. | Thienopyridinone compounds and methods of treatment |
CA2508585A1 (en) * | 2004-06-01 | 2005-12-01 | Axonyx, Inc. | Transdermal delivery system for treatment of cognitive disorders |
EP1604686A1 (de) * | 2004-06-08 | 2005-12-14 | Axonyx, Inc. | Verwendung von Phenserine und einem HMG CoA reduktase Hemmer zur Verzögerung der Alzheimer Krankheit |
US7407966B2 (en) | 2004-10-07 | 2008-08-05 | Epix Delaware, Inc. | Thienopyridinone compounds and methods of treatment |
US7598265B2 (en) | 2004-09-30 | 2009-10-06 | Epix Delaware, Inc. | Compositions and methods for treating CNS disorders |
US7576211B2 (en) | 2004-09-30 | 2009-08-18 | Epix Delaware, Inc. | Synthesis of thienopyridinone compounds and related intermediates |
US20060194723A1 (en) * | 2005-02-28 | 2006-08-31 | Rabinoff Michael D | Novel medication treatment and delivery strategies for Alzheimer's Disease, other disorders with memory impairment, and possible treatment strategies for memory improvement |
WO2006138385A2 (en) * | 2005-06-14 | 2006-12-28 | Cancog Technologies Inc.24 | Use of phenserine and analogs to treat behavioral problems and improve trainability |
EP2125709A2 (de) * | 2007-02-02 | 2009-12-02 | Colucid Pharmaceuticals, Inc. | Verbindungen zur hemmung von cholinesterase |
RU2327480C1 (ru) | 2007-05-23 | 2008-06-27 | Виктор Иванович Рощин | Активный ингредиент лекарственного средства, лекарственное средство, фармацевтическая композиция и способ лечения больных с дементным синдромом |
US20090048229A1 (en) * | 2007-07-18 | 2009-02-19 | Rupniak Nadia M J | Methods for promoting wakefulness |
US8593728B2 (en) * | 2009-02-19 | 2013-11-26 | Toyota Motor Engineering & Manufacturing North America, Inc. | Multilayer photonic structures |
EP2445877B1 (de) | 2008-12-03 | 2014-07-23 | Nanotherapeutics, Inc. | Bicyclische verbindungen und verfahren zu deren herstellung und deren verwendung |
EP2453890B1 (de) * | 2009-07-17 | 2020-05-27 | Allergan, Inc. | Zusammensetzungen mit einem cholinesterasehemmer zur behandlung von kognitiven beeinträchtigungen |
US20120225922A1 (en) * | 2011-03-04 | 2012-09-06 | Qr Pharma | Effective Amounts of (3aR)-1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo [2,3-b]indol-5-yl Phenylcarbamate and Methods of Treating or Preventing Neurodegeneration |
US10111860B1 (en) | 2016-01-15 | 2018-10-30 | Aristea Translational Medicine Corporation | Compositions and methods for treating concussion |
US10864192B2 (en) | 2016-01-15 | 2020-12-15 | Aristea Translational Medicine Corporation | Compositions and methods for inhibiting brain trauma-induced neurodegeneration and related conditions |
CA3083015A1 (en) | 2017-05-24 | 2018-11-28 | Qr Pharma, Inc. | Prevention or treatment of disease states due to metal dis-homeostasis via administration of posiphen to healthy or sick humans |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US479107A (en) * | 1892-07-19 | oesterreich | ||
US4791107A (en) * | 1986-07-16 | 1988-12-13 | Hoechst-Roussel Pharmaceuticals, Inc. | Memory enhancing and analgesic 1,2,3,3A,8,8A-hexahydro-3A,8 (and) 1,3A,8)-di(and tri)methylpyrrolo(2,3-B)indoles, compositions and use |
DE3843239C1 (de) * | 1988-12-22 | 1990-02-22 | Lohmann Therapie Syst Lts | |
US4971992A (en) * | 1989-03-27 | 1990-11-20 | Hoechst-Roussel Pharmaceuticals Inc. | Carbonate derivatives of eseroline |
US4996201A (en) * | 1989-08-02 | 1991-02-26 | Warner-Lambert Co. | 4-(N-substituted amino)-2-butynyl-1-carbamates and thiocarbamates and derivatives thereof as centrally acting muscarinic agents |
US4914102A (en) * | 1989-09-28 | 1990-04-03 | Hoechst Roussel Pharmaceuticals, Inc. | N-aminocarbamates related to physostigmine, pharmacentical compositions and use |
US5077289A (en) * | 1989-11-30 | 1991-12-31 | Hoechst Roussel Pharmaceuticals Inc. | Memory enhancing and analgesic aminocarbonylcarbamates related to physostigmine |
US5171750A (en) * | 1991-09-26 | 1992-12-15 | The United States Of America As Represented By The Department Of Health And Human Services | Substituted phenserines as specific inhibitors of acetylcholinesterase |
-
1992
- 1992-11-23 US US07/980,399 patent/US5409948A/en not_active Expired - Lifetime
-
1993
- 1993-11-23 JP JP51335894A patent/JP3778363B2/ja not_active Expired - Fee Related
- 1993-11-23 PT PT94903295T patent/PT668763E/pt unknown
- 1993-11-23 AT AT94903295T patent/ATE213411T1/de not_active IP Right Cessation
- 1993-11-23 CA CA002149924A patent/CA2149924C/en not_active Expired - Fee Related
- 1993-11-23 DK DK94903295T patent/DK0668763T3/da active
- 1993-11-23 WO PCT/US1993/011423 patent/WO1994012176A1/en active IP Right Grant
- 1993-11-23 ES ES94903295T patent/ES2173111T3/es not_active Expired - Lifetime
- 1993-11-23 DE DE69331605T patent/DE69331605T2/de not_active Expired - Fee Related
- 1993-11-23 AU AU57290/94A patent/AU693428B2/en not_active Ceased
- 1993-11-23 EP EP94903295A patent/EP0668763B1/de not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
DE69331605D1 (de) | 2002-03-28 |
CA2149924C (en) | 2006-01-31 |
ES2173111T3 (es) | 2002-10-16 |
CA2149924A1 (en) | 1994-06-09 |
AU5729094A (en) | 1994-06-22 |
JPH08505130A (ja) | 1996-06-04 |
US5409948A (en) | 1995-04-25 |
WO1994012176A1 (en) | 1994-06-09 |
PT668763E (pt) | 2002-08-30 |
EP0668763A1 (de) | 1995-08-30 |
JP3778363B2 (ja) | 2006-05-24 |
AU693428B2 (en) | 1998-07-02 |
DK0668763T3 (da) | 2002-06-03 |
EP0668763B1 (de) | 2002-02-20 |
DE69331605T2 (de) | 2002-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE213411T1 (de) | Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen | |
DE58902094D1 (de) | Kombinationspraeparat zur behandlung von nervenzell-und nervenfasererkrankungen und verletzungen. | |
DE69739792D1 (de) | Verfahren zur Behandlung von Augenerkrankungen | |
DE69428130T2 (de) | Verwendung von bcl-2 zur herstellung von arzneimitteln zur therapeutischen behandlung und verhinderung von krankheiten | |
DE69825292D1 (de) | Verwendung von inosine zur herstellung eines medikamentes zur stimulierung des axonwachstums von zns-neuronen | |
ATE94069T1 (de) | Verwendung von physiologisch wirksamen substanzen zur herstellung von medikamenten fuer gehirn- und nervenerkrankungen. | |
DE10199020I2 (de) | Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit. | |
DE69230046T2 (de) | 2-Bromomelatonin zur Behandlung von Schlafstörungen | |
ATE127342T1 (de) | Verwendung von modafinil zur herstellung eines antiischämischen arzneimittels. | |
DE69631478D1 (de) | Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen | |
ATE141505T1 (de) | Verwendung von 3-guanidinopropionsäure zur herstellung eines medikaments zur behandlung und prävention von fettsucht | |
DE69424777T2 (de) | 3,4-diarylchromane zur behandlung von dermatitis | |
ATE137965T1 (de) | Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege | |
ATE220923T1 (de) | Rekombinante adenoviren und deren verwendung in der gentherapie zur behandlung von augenerkrankungen | |
ATE196738T1 (de) | Verwendung von immunglobulin-präparationen zur herstellung eines medikaments zur oralen verabreichung zur behandlung und prophylaxe chronischer schmerzzustände | |
DE69304843D1 (de) | Methode zur Behandlung von Haarausfall | |
ATA901396A (de) | Verwendung von melatonin zur behandlung von an medikamentensucht leidenden patienten | |
DE69300037D1 (de) | Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria. | |
DE69424415D1 (de) | Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit | |
ATE230608T1 (de) | Verwendung von bradykinin-antagonisten zur herstellung von arzneimitteln zur behandlung und prävention der alzheimer'schen krankheit | |
ATE295731T1 (de) | Olanzapine zur behandlung von drogenmissbrauch | |
ATE79759T1 (de) | Kombinationspraeparat zur behandlung von nervenzell-und nervenfasererkrankungen und verletzungen. | |
DE69311286D1 (de) | Verwendung von Melatonin zur Herstellung eines Arzneimittels zur Behandlung von Scleroderma und der Sarcoidosis | |
ATE88090T1 (de) | Verwendung von acetyl-d-carnitin zur therapeutischen behandlung von glaukom. | |
DE69218544D1 (de) | Verwendung von BMY 14802 zur Behandlung von Angstzuständen bei Patienten mit Benzodiazepin-Entzugserscheinungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification | ||
REN | Ceased due to non-payment of the annual fee |